Scholar Rock begins Phase 2 FORGE trial of apitegromab in facioscapulohumeral muscular dystrophy
SRRK•Phase 2 FORGE trial begins dosing
Scholar Rock received FDA Fast Track designation for apitegromab in facioscapulohumeral muscular dystrophy, adding to its Orphan Drug status.
Participant dosing has started in the Phase 2 FORGE trial, positioning the program as a new clinical catalyst for the pipeline.
Results have not been presented; the study is designed to read out whether apitegromab can increase lean muscle and support functional improvement.
The program builds on prior late-stage evidence in spinal muscular atrophy showing motor-function improvement, supporting commercial upside if replicated in FSHD.
